Literature DB >> 31339589

FASTlab Radiosynthesis of the 18 F-labelled HER2-binding Affibody molecule [18 F]GE-226.

Peter B Iveson1, Matthias Glaser1,2, Bard Indrevoll3, Jonathan Shales1, Dimitrios Mantzilas3, Lone Omtvedt3, Sajinder K Luthra1, Duncan Hiscock1, Julian Grigg1.   

Abstract

An 18 F-labelled human epidermal growth factor receptor (HER2) receptor binding radiotracer is a potential tool to non-invasively identify HER2 positive tumour lesions in subjects with recurrent metastatic breast cancer. Having explored the manual radiochemistry to conjugate the Affibody molecule ZHER2:2891 with [18 F]4-fluorobenzaldehyde, we have developed and optimised a full protocol for the automated GE FASTlab synthesiser. Our chemometric model predicted the best radiochemical purity for a short conjugation time (2.8 minutes), a low temperature (65°C), and a medium Affibody molecule precursor amount (5.5 mg). Under these optimised conditions, [18 F]GE-226 was produced after solid-phase extraction purification with activity yield of 30% ± 7 (n = 18) and a radiochemical purity of 94% ± 2 (n = 18). The synthesis and purification was complete after 43 minutes and provided apparent molar activities of 12 to 30 GBq/μmol (n = 12) at the end of synthesis.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Affibody; Her2; PET diagnostics; molecular imaging

Year:  2019        PMID: 31339589     DOI: 10.1002/jlcr.3789

Source DB:  PubMed          Journal:  J Labelled Comp Radiopharm        ISSN: 0362-4803            Impact factor:   1.921


  3 in total

Review 1.  Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer.

Authors:  Xianwen Hu; Dandan Li; Yujie Fu; Jiashen Zheng; Zelong Feng; Jiong Cai; Pan Wang
Journal:  Front Oncol       Date:  2022-06-15       Impact factor: 5.738

2.  Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment.

Authors:  Zhengyuan Zhou; Rebecca Meshaw; Michael R Zalutsky; Ganesan Vaidyanathan
Journal:  J Nucl Med       Date:  2021-02-26       Impact factor: 11.082

Review 3.  Affibody Molecules as Targeting Vectors for PET Imaging.

Authors:  Vladimir Tolmachev; Anna Orlova
Journal:  Cancers (Basel)       Date:  2020-03-11       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.